Study participants receiving apomorphine also gave their treatment higher effectiveness scores than those who received the placebo.
Browsing: Movement disorders
In this review, the authors discuss the history of DBS for Parkinson’s disease, as well as outcomes, recent advances, and where the field will go next.
The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for Parkinson’s disease.
Curt Freed discusses his pioneering work on transplanting human fetal dopaminergic cells, and where Parkinson’s disease research and treatment is heading in the next decade.
The randomized, placebo-controlled Phase I-II clinical study will investigate CDNF delivered with Renishaw’s chronic drug delivery system in Parkinson’s disease patients.
This article examines a number of different disease-modifying therapy strategies for the treatment of relapsing-remitting multiple sclerosis.
A researcher’s own experiences have led to further understanding of the repair process needed for multiple sclerosis.
In this interview, Dr Akassoglou discusses her pioneering research, as well as the key challenges in this exciting area of neuroscience and her hopes for the field.
Dr Paul Gallagher (Institute of Neurological Sciences, Glasgow, UK) provides an overview of these two recent papers by Jokubaitis and colleagues  and Cree and colleagues, which both assessed factors predictive of long-term disability outcomes in people with multiple sclerosis (MS).
In this interview, Drs Silverman and Buscher discuss their work, and how these two rare diseases are shedding light not only on each other, but also a wealth of other neurological disorders.